Zacks: Analysts Expect Aldeyra Therapeutics, Inc (ALDX) Will Announce Earnings of -$0.37 Per Share

Brokerages forecast that Aldeyra Therapeutics, Inc (NASDAQ:ALDX) will report ($0.37) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings. Aldeyra Therapeutics also posted earnings per share of ($0.37) in the same quarter last year. The business is expected to report its next earnings report on Monday, May 21st.

According to Zacks, analysts expect that Aldeyra Therapeutics will report full-year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($1.67) to ($1.51). For the next year, analysts expect that the company will report earnings of ($2.06) per share, with EPS estimates ranging from ($3.08) to ($1.51). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Aldeyra Therapeutics.

How to Become a New Pot Stock Millionaire

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, March 29th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.04).

Several research analysts have issued reports on the stock. Seaport Global Securities assumed coverage on shares of Aldeyra Therapeutics in a research report on Friday, January 26th. They issued a “buy” rating and a $13.00 price target on the stock. ValuEngine upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald set a $23.00 price target on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 29th. Cowen reiterated a “hold” rating on shares of Aldeyra Therapeutics in a research report on Monday, April 9th. Finally, Zacks Investment Research cut shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $16.93.

Aldeyra Therapeutics stock traded up $0.10 during mid-day trading on Tuesday, hitting $7.10. The company’s stock had a trading volume of 16,952 shares, compared to its average volume of 95,209. The company has a debt-to-equity ratio of 0.03, a quick ratio of 13.12 and a current ratio of 13.12. The firm has a market cap of $139.62, a price-to-earnings ratio of -5.04 and a beta of 0.56. Aldeyra Therapeutics has a twelve month low of $3.80 and a twelve month high of $11.90.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALDX. Vanguard Group Inc. grew its position in Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Aldeyra Therapeutics during the 3rd quarter valued at $134,000. Woodstock Corp boosted its stake in shares of Aldeyra Therapeutics by 20.4% during the 4th quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 9,850 shares during the period. Geode Capital Management LLC boosted its stake in shares of Aldeyra Therapeutics by 34.6% during the 4th quarter. Geode Capital Management LLC now owns 102,263 shares of the biotechnology company’s stock valued at $695,000 after buying an additional 26,269 shares during the period. Finally, Mangrove Partners acquired a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at $1,118,000. Hedge funds and other institutional investors own 49.74% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect Aldeyra Therapeutics, Inc (ALDX) Will Announce Earnings of -$0.37 Per Share” was published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://zolmax.com/investing/zacks-analysts-expect-aldeyra-therapeutics-inc-aldx-will-announce-earnings-of-0-37-per-share/2112443.html.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

-$0.25 Earnings Per Share Expected for Aralez Pharmaceuticals  This Quarter
-$0.25 Earnings Per Share Expected for Aralez Pharmaceuticals This Quarter
Zacks: Analysts Expect Aldeyra Therapeutics, Inc  Will Announce Earnings of -$0.37 Per Share
Zacks: Analysts Expect Aldeyra Therapeutics, Inc Will Announce Earnings of -$0.37 Per Share
Synergy Pharmaceuticals  Earns News Sentiment Rating of 0.05
Synergy Pharmaceuticals Earns News Sentiment Rating of 0.05
UMH Properties  Given Daily Media Sentiment Rating of 0.19
UMH Properties Given Daily Media Sentiment Rating of 0.19
Somewhat Positive News Coverage Somewhat Unlikely to Affect USA Technologies  Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Affect USA Technologies Stock Price
Ashmore Group’s  “Buy” Rating Reaffirmed at Canaccord Genuity
Ashmore Group’s “Buy” Rating Reaffirmed at Canaccord Genuity


Leave a Reply

 
© 2006-2018 Zolmax.